Participated · Series C · Jul 2026

Trellis Bioscience uses a proprietary technology to clone human antibodies from white blood cells and develops native human monoclonal antibodies to address difficult infectious diseases. Its lead program, calpurbatug (TRL1068), is an investigational monoclonal antibody aimed at disrupting biofilms and is in a Phase 2 trial for chronic prosthetic joint infections. The company also has a pipeline of antiviral antibodies, one of which is in a clinical trial. Trellis highlights that human antibodies have a lower toxicity-related failure rate than other drug classes and that its discovery approach isolates antibodies from recovered patients. The company is based in Redwood City, CA. To date Trellis has raised approximately $35 million in equity, complemented by a comparable amount of non-dilutive grant funding from NIAID and CARB-X.

Participated · Series C · Oct 2017

Claret Medical is a privately held medtech company that developed the Sentinel dual-filter cerebral protection system, the first FDA-cleared device for transcatheter aortic valve replacement (TAVR). The company has commercialized Sentinel across Europe, selected Asia Pacific countries and recently in the U.S., where it completed a controlled commercial release. Claret has conducted a structured clinical program including three randomized studies and more than 2,300 patients, and reports that over 5,000 patients have benefited from its technology. The company highlights data showing Sentinel reduces periprocedural TAVR stroke by 70 percent. Claret plans to use new financing to support market access programs, research and development of next-generation products, and expansion of its commercial organization to build on U.S. commercialization. Claret Medical develops the Sentinel Cerebral Protection System (CPS), a filter-based device that captures and removes embolic debris released during transcatheter aortic valve replacement (TAVR) and other procedures. The company is focused on addressing stroke risk during TAVR through product development and clinical research. Sentinel CPS received Investigational Device Exemption (IDE) approval earlier this year and has been used in more than 800 procedures worldwide to date. Claret is embarking on the SENTINEL pivotal U.S. trial to evaluate reductions in number and size of new ischemic brain lesions and potential neurocognitive benefits, and plans two additional studies of structural heart procedures. The company is privately held and headquartered in Santa Rosa, California. Claret Medical is a California-based medical device company that makes the Montage Dual Filter embolic protection system, designed to capture embolic debris during transcatheter aortic valve implantation (TAVI) procedures. The device won CE Mark approval in the European Union earlier in the year. Published research enrolled 40 TAVI patients and reported the filter captured debris traveling toward the brain in 75% of patients, with captured particles ranging from 0.55 mm to 1.8 mm and consisting largely of fibrin likely from native aortic valve leaflets or the aortic wall. Financially, Claret has raised $3.6 million so far through a private offering of convertible promissory notes participated in by 28 unnamed investors. The company launched the financing in July 2012 and said it aims to raise a total of $4 million, needing another $375,000 before the offering expires in August 2015. Claret Medical is a Santa Rosa, Calif.-based medical device maker focused on embolic protection during vascular procedures. The company landed a CE Mark for its Montage system to protect against brain embolism in vascular surgery. Montage is described as the first filtration system to protect both carotid arteries simultaneously and is delivered during intravascular procedures such as transcatheter aortic valve intervention (TAVI). The catheter can remove potentially stroke-causing embolic material from the body. Claret recently raised $3.38 million in a Series A private equity offering, according to an SEC report. Clinicians quoted in the article said the CE Mark approval is an important step that could potentially reduce stroke rates in TAVI and other vascular procedures.

Participated · Series C · Jun 2016

Bluesight develops Medication Intelligence™ solutions that bring visibility and predictability to medication management, including KitCheck™ (RFID-enabled kit and tray management), ControlCheck™ (controlled substance diversion management) and CostCheck™ (drug purchasing optimization). Led by CEO Kevin MacDonald, the company applies AI and machine learning to surface actionable analytics that help health systems improve efficiency, reduce medication costs, and increase compliance and safety. More than 1,000 U.S. and Canadian hospitals use its solutions. Bluesight received a strategic growth investment from Thoma Bravo; the amount was not disclosed. The company intends to use the funds to further enhance drug diversion prevention through its acquisition of Medacist and to grow its inventory management and spend optimization offerings. The acquisition of Medacist will combine auditing capabilities and reporting tools to serve more than 2,000 hospitals across North America, providing unified visibility into medication usage and diversion. Kit Check offers cloud-based and Internet of Things (IoT) software to automate hospital pharmacy kit processing, medication tracking, and restocking, replacing manual processes. The company serves over 250 hospital pharmacies with 15,000 users across the United States and Canada. Led by co-founder and CEO Kevin MacDonald, Kit Check plans to use new funding to expand market share and extend its solutions. The company is based in Washington, DC. Kit Check has raised $37.4M to date, including the most recent round. The product focus is on reducing time-consuming and error-prone manual medication handling in hospitals. Kit Check is a Washington, D.C.-based provider of hospital pharmacy kit processing and medication tracking software. Its products include Kit Check for automated pharmacy kit medication restocking and Anesthesia Check for automated anesthesia medication tracking, validation and syringe-level recording. The company serves approximately 145 hospital pharmacies across the United States. Founded in 2012 by CEO Kevin MacDonald, Kit Check has raised $22.4M to date. It intends to use the new funds to further extend its product portfolio and drive customer growth. As part of the financing, Dave Schulte of Kaiser Permanente Ventures will join Kit Check’s board. Kit Check offers a cloud-based software platform paired with RFID-outfitted scanning stations to automate inventory of hospital pharmacy kits (code trays, crash carts, anesthesiology kits). The company says its scans can cut manual processing from 30+ minutes to about 3 minutes and that several customers have reduced out-of-date kit rates from roughly 20% to under 1%. Its system can be installed in less than one hour and requires no on-site installation or in-house IT support. Customers include the University of Maryland Medical Center, NYU Langone Medical Center and five other paying hospitals, with nine more hospitals expected to begin rollouts in the coming months. Kit Check graduated Rock Health’s accelerator with $100K in seed capital. The startup plans to use new funding to accelerate growth and expand its sales force and delivery staff. Kit Check positions its use of RFID, rather than barcodes, as a primary differentiator vs. competitors such as MedKeeper.

Participated · Series A · Aug 2015

WellTrackONE offers a platform to automate annual wellness exam administration and identify reimbursement opportunities for physician practices. Its clinical triggers product scans data from the wellness exam tool to generate treatment and referral recommendations that can be billed to Medicare. Other products include a risk management tool for Accountable Care Organizations, Reportal Analytics, and an EHR integration product called CCD Extractor. The company aims to curb avoidable hospital expenses by reducing fall risk and identifying early chronic conditions. WellTrackONE plans further product development and market expansion into Medicare Advantage, Commercial, and Medicaid managed care organizations. It also has strategic relationships with partners such as MD Revolution and an agreement with Office Ally to support Medicare patients. Based in Hilton Head Island, SC, WellTrackONE offers a complete program for scheduling, staffing and documentation built around a proprietary evidence-based risk stratification engine. The platform enables practices to perform Annual Wellness Visits for Medicare patients without changing physician workflow or adding administrative burden. It captures outcomes and clinical measurement data while generating significant revenue for provider organizations. The company plans to use recent financing to expand sales and marketing across the United States. Management also intends to add technologies to its flagship data management system to enhance the product offering. The article does not disclose operating metrics or prior financing rounds.

Led · Equity · Jun 2015

Led by CEO Leah Sparks, Wildflower Health builds digital and value-based care solutions for obstetric providers and payers. Its platform helps providers evaluate and design value-based care (VBC) models, install digital health and point-of-care decision-support tools, and adapt workflows to VBC requirements. The company continuously processes clinical and financial data to surface real-time clinical metrics and to manage payments, reconciliations, and outcomes measurement. Its proprietary maternity bundle spans prenatal to postnatal care and accounts for the total cost of pregnancy for both mother and baby. Wildflower plans to use new funding to strengthen its internal team and to prepare for nationwide expansion of that maternity bundle. Providence has increased its financial commitment and expanded a contract to install Wildflower’s solution across Southern California. Wildflower Health is a San Francisco-based mobile health software company that connects families to health resources on their smartphones. Its tools promote healthy pregnancies, track family health, and support the growth of each family member based on individual health needs over time. The company launched its Family Health platform, an integrated application to manage pregnancy and family health. Over the past year it tripled its recurring license revenue and expanded its user base by more than 10x. Led by founder and CEO Leah Sparks, Wildflower plans to use new funding to continue organizational growth and expand its Family Health platform. Wildflower Health builds Due Date Plus, a mobile maternity program that functions as a patient-navigation tool configurable by health plans to show coverage details and in‑network providers. The app is HIPAA‑compliant and is used by payers including Aetna, LifeMap and state Medicaid programs such as Wyoming’s. The company plans to broaden its product portfolio into pediatrics and family health and will launch a Spanish version of Due Date Plus in the coming months. Wildflower also agreed to a strategic partnership with Everyday Health, operator of the What to Expect franchise that reaches about 75% of pregnant women in the U.S. The new funding will support strategic expansion and ongoing product development. Wildflower Health offers Due Date Plus, a mobile maternity program available on iOS and Android that uses self-reported data to identify high-risk pregnancies and drive interventions. The app delivers customized tools and content and refers users to care management programs. The company plans to expand its mobile health offering to health plans, self-insured employers and Medicaid clients using the new funding. Wildflower was founded in 2012 by CEO Leah Sparks and Kathy Bellevin. Prior to this round the company secured seed funding in late 2012 through Rock Health.